AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

KIORA PHARMACEUTICALS INC Director's Dealing 2018

Jul 12, 2018

35256_dirs_2018-07-12_ae737566-e03f-449e-b23d-6c7cb101160d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EYEGATE PHARMACEUTICALS INC (EYEG)
CIK: 0001372514
Period of Report: 2018-07-10

Reporting Person: Wirostko Barbara (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-07-10	Common Stock	A	175000	—	Acquired	424997	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	59915	Indirect

Footnotes

F1: Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The restrictions will vest as to one-third (1/3) of the shares on July 10, 2019, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.